U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07835893) titled 'Lenvatinib Plus Chemotherapy for pNET Liver Metastases' on Sept. 17.
Brief Summary: This prospective, non-randomized, concurrent parallel-controlled study will evaluate treatment response and resistance mechanisms in patients with pancreatic neuroendocrine tumors with liver metastases (pNET-LM) receiving second-line systemic therapy after failure of first-line treatment.
Eligible patients will receive either lenvatinib combined with chemotherapy or chemotherapy alone according to the study protocol and clinical treatment strategy. The clinical efficacy and safety of the two treatment strategies will be evaluated using objective re...